This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion. RWE Cohort: HR 1.01 (0.83-1.22) RCT-dup Cohort: HR 1.19 (0.86-1.64) ORAL Surveillance: HR 1.48 (1.04-2.09) Interesting day 4 ahead! great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr

Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m

TOFA Post hoc analysis on 2000pts: ⬆️ Paraoxonase PON1 activity associated w/ ⬇ risk of malignancies (not NMSC) in RA pts treated w/ TOFA, Adj on RA duration, age, and smoking. A promising biomarker! #Abst980 @RheumNow #ACR21 https://t.co/fOILnAyDN9

#ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest

• https://bit.ly/3H1GMDI

ORAL Surveillance MACE conclusions: So this is fair: tofacitinib acts as a CV risk factor, there are many others, we need to address CV risk in RA pts. Nevertheless, in terms of MI risk, tofa vs TNFi, if I had one CV risk factor, I know what I'd do. #ACR21 ABST0958 @RheumNow https://t.co/4Z79XtTzl9

SELECT-AXIS 1: UPA 15 mg QD consistently efficacious over 2 years for ASAS40. Low radiographic progression rates in AS pts. No new safety findings were observed. Abs 0924 #ACR21 #RheumNow @RheumNow https://t.co/CWvH1OPGyR https://t.co/uC67fJZDCE

• Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondyli…

Abst0509 #ACR21 @RheumNow study of plasma concentrations of Deucravacitinib show high functional selectivity for TYK2 while Tofa, Upa & Bari inhibit JAK1/2/3 to varying degrees show no meaningful inhibition of TYK2. Distinct class of kinase inhibitor as compared to JAKs

With Deucravacitinib, a TYK2 inhibitor vs placebo, PsAID-12 and PsAID-9 scores were significantly improved versus baseline at Week 16 and other PROs showing a clear improvement in PsA-related impact @RheumNow #ACR21 Abst#0750 https://t.co/JbeSE2dO94 https://t.co/pH79dXCYSs

• Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Question…